Colistin is a last-resort antibiotic critical for treating multidrug-resistant bacterial infections. Resistance to colistin heralds the emergence of truly pan-resistant infections. In the article, the researchers found combining colistin with inhibitors of biotin (vitamin B7) or fatty acid production can overcome colistin resistance.